Login to Your Account



Isis investors find hope in positive phase II diabetes data

By Michael Fitzhugh
Staff Writer

Wednesday, May 14, 2014
Isis Pharmaceuticals Inc. shares (NASDAQ:ISIS) extended a slow recovery Wednesday as investors took note of phase II data showing that the company's experimental antisense drug, ISIS-GCGRRx, helped patients with type 2 diabetes improve control of the disease, even when they're unable to do so with metformin.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription